1. 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD)-Inducible Poly-ADP-Ribose Polymerase (TIPARP/PARP7) Catalytic Mutant Mice (TiparpH532A) Exhibit Increased Sensitivity to TCDD-Induced Hepatotoxicity and Lethality
- Author
-
David Hutin, Kim S. Sugamori, Peng Shao, Sachin Kumar Singh, Solveig Pettersen, Ninni Elise Olafsen, Giulia Grimaldi, Marit Rasmussen, Jason Matthews, Denis M. Grant, and Alexandra S. Long
- Subjects
Molecular, Biochemical, and Systems Toxicology ,0301 basic medicine ,AcademicSubjects/SCI01040 ,Polychlorinated Dibenzodioxins ,CYP1B1 ,Mutant ,TCDD-inducible poly-ADP-ribose polymerase (TIPARP) ,wasting syndrome ,Toxicology ,medicine.disease_cause ,Mice ,03 medical and health sciences ,0302 clinical medicine ,TCDD-Inducible Poly [ADP-Ribose] Polymerase ,medicine ,Animals ,2,3,7,8-tetrachlorodibenzo-p-dioxin ,Adenosine Diphosphate Ribose ,Mutation ,AcademicSubjects/MED00305 ,biology ,aryl hydrocarbon receptor ,Chemistry ,Fibroblasts ,ADP-ribosyltransferase diphtheria toxin-like 14 (ARTD14) ,Aryl hydrocarbon receptor ,medicine.disease ,Molecular biology ,Featured ,3. Good health ,poly-ADP-ribose polymerase 7 (PARP7) ,030104 developmental biology ,Receptors, Aryl Hydrocarbon ,ADP-ribosylation ,Toxicity ,biology.protein ,Chemical and Drug Induced Liver Injury ,Steatohepatitis ,030217 neurology & neurosurgery - Abstract
2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD)-inducible poly-adenosine diphosphate (ADP)-ribose polymerase (TIPARP/PARP7), an aryl hydrocarbon receptor (AHR) target gene and mono-ADP-ribosyltransferase, acts as part of a negative feedback loop to repress AHR signaling. This process is prevented by a single H532A mutation in TIPARP that destroys its catalytic activity. We hypothesized that the loss of TIPARP catalytic activity would increase sensitivity to TCDD-induced toxicity in vivo. To test this, we created a catalytically deficient mouse line (TiparpH532A) by introducing a single H532A mutation in TIPARP. Treatment of mouse embryonic fibroblasts or hepatocytes isolated from TiparpH532A mice confirmed the increased TCDD-induced expression of the AHR target genes Cyp1a1, Cyp1b1, and Tiparp. TiparpH532A mice given a single injection of 10 µg/kg TCDD, a nonlethal dose in Tiparp+/+ mice, did not survive beyond day 10. All Tiparp+/+ mice survived the 30-day treatment. TCDD-treated TiparpH532A mice displayed increased expression of AHR target genes, increased steatohepatitis and hepatotoxicity. Hepatic RNA-sequencing revealed 7-fold more differentially expressed genes in TiparpH532A mice than in Tiparp+/+ mice (4542 vs 647 genes) 6 days after TCDD treatment. Differentially expressed genes included genes involved in xenobiotic metabolism, lipid homeostasis and inflammation. Taken together, these data further support TIPARP as a critical negative regulator of AHR activity and show that loss of its catalytic activity is sufficient to increase sensitivity to TCDD-induced steatohepatitis and lethality. Since TIPARP inhibition has recently emerged as a potential anticancer therapy, the impact on AHR signaling, TCDD and polycyclic aromatic hydrocarbon toxicity will need to be carefully considered under conditions of therapeutic TIPARP inhibition.
- Published
- 2021
- Full Text
- View/download PDF